Efficacy and safety of patiromer for non-dialysis and dialysis patients with hyperkalemia: the randomized, placebo-controlled and long-term study
Clinical and Experimental Nephrology · 2025
DOI: 10.1007/s10157-024-02585-5 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Clinical and Experimental Nephrology, 2025. Verfasst von Naoki Kashihara und 8 weiteren Autor:innen. Beteiligte Einrichtung: Kawasaki Medical School, Okayama, Japan. Hauptthemen laut MEDLINE: Hyperkalemia, Polymers, Potassium. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: AstraZeneca, Gilead Sciences, Kyowa Kirin.
Abstract (Originalsprache)
Background
The objectives of this phase two study are to investigate the efficacy of two starting doses of 8.4 g and 16.8 g and evaluate the long-term safety of patiromer in Japanese patients with hyperkalemia.
Methods
This study comprised three cohorts; non-dialysis patients with baseline serum potassium (sK) level of 5.1 to < 6.0 mmol/L (NDC1); 6.0 to < 6.5 mmol/L (NDC2); dialysis patients with baseline sK level of 5.5 to < 6.5 mmol/L (DC). The study design was one-week, randomized, double-blind, placebo-controlled, and open label extension for one year in NDC1, open label during the study in NDC2 and DC. Patients were randomly assigned to patiromer 8.4 g, 16.8 g or placebo in NDC1, 8.4 g or 16.8 g in NDC2 and DC. Dose was adjusted up to 25.2 g according to the titration algorism in open label period.
Results
A total of 185 patients were randomized (NDC1:153, NDC2:10, and DC:22). The primary endpoint of the change in least squares mean sK levels at Week 1 in NDC1 was – 0.55, – 0.77 and – 0.10 mmol/L for the 8.4 g, 16.8 g and placebo group ( P < 0.001 for the patiromer group vs the placebo group). In all cohorts for each patiromer group, more than 80% of patients achieved normal sK at Week 5. There was no severe treatment-related adverse event.
Conclusion
Treatment with patiromer was effective in lowering and maintaining target sK levels, also well tolerated for one year in Japanese patients with hyperkalemia.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Kawasaki Medical School, Okayama, Japan.
- Minamiosaka Hospital, Osaka, Japan.
- Higashi Takarazuka, Satoh Hospital, Hyogo, Japan.
- JA Toride Medical Center, Ibaraki, Japan.
- Tsukuba Central Hospital, Ibaraki, Japan.
- Kokura Memorial Hospital, Fukuoka, Japan.
Förderung
- AstraZeneca
- Gilead Sciences
- Kyowa Kirin
- GlaxoSmithKline Japan
- Daiichi-Sankyo
- Takeda Pharmaceutical Company
- Astellas Pharma
- Otsuka Pharmaceutical
Zitieren
APA
Kashihara, N., Kumeda, Y., Higashino, Y., Maeda, Y., Kaneko, Y., Kanai, H., Taniguchi, Y., Ishii, T., & Tomioka, Y. (2025). Efficacy and safety of patiromer for non-dialysis and dialysis patients with hyperkalemia: the randomized, placebo-controlled and long-term study. Clinical and Experimental Nephrology. https://doi.org/10.1007/s10157-024-02585-5
Vancouver
Kashihara N, Kumeda Y, Higashino Y, Maeda Y, Kaneko Y, Kanai H, et al. Efficacy and safety of patiromer for non-dialysis and dialysis patients with hyperkalemia: the randomized, placebo-controlled and long-term study. Clinical and Experimental Nephrology. 2025. doi:10.1007/s10157-024-02585-5
BibTeX
@article{Kashihara2025,
author = {Kashihara, Naoki and Kumeda, Yasuro and Higashino, Yorihiko and Maeda, Yoshitaka and Kaneko, Yoko and Kanai, Hidetoshi and Taniguchi, Yuko and Ishii, Takayuki and Tomioka, Yusuke},
title = {Efficacy and safety of patiromer for non-dialysis and dialysis patients with hyperkalemia: the randomized, placebo-controlled and long-term study},
journal = {Clinical and Experimental Nephrology},
year = {2025},
doi = {10.1007/s10157-024-02585-5}
}
EUVIMED